GleamWall
中文EN

BNGO Bionano Genomics, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1411690 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.2%
TTM net income YoY22.0%
TTM EPS YoY84.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin48.0%
Operating margin-97.1%
Net margin-96.9%
FCF margin—
EBITDA margin-76.0%

Returns

ROE-77.2%
ROA-48.0%
ROIC (approx.)-67.6%
Asset turnover0.50x

Leverage & solvency

Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-17.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$28.51M$30.78M
Cost of revenue$15.32M$30.40M
Gross profit$13.19M$380,000
R&D expense$11.37M$24.80M
SG&A expense$35.15M$51.85M
Operating income-$33.34M-$103.98M
Pretax income-$26.33M-$111.98M
Income tax$67,000$33,000
Net income-$26.39M-$112.02M
EBITDA-$23.81M-$89.96M
EPS (basic)-4.85-88.13
EPS (diluted)-4.85-88.13
Weighted avg. shares (diluted)5.45M1.27M
Balance sheet
Cash & equivalents$2.99M$9.17M
Short-term investments$16.28M$302,000
Receivables$5.20M$4.75M
Inventory$7.83M$13.28M
Current assets$45.39M$39.49M
PP&E, net$14.85M$19.22M
Intangibles$4.34M$9.71M
Total assets$73.58M$76.67M
Current liabilities$22.94M$37.34M
Total liabilities$29.16M$41.30M
Shareholders' equity$44.42M$35.38M
Shares outstanding10.74M1.87M
Cash flow statement
Operating cash flow-$16.34M-$68.92M
Investing cash flow-$12.75M$73.84M
Financing cash flow$24.04M-$13.69M
Depreciation & amortization$9.53M$14.02M
Stock-based compensation$4.53M$9.74M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.